PETACH TIKVA, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that it will report its third quarter 2026 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 11, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of management, the Company recommends listening via the webcast.

Conference Call Dial-In & Webcast Information:

Date: Wednesday, November 11, 2026
Time: 8:30 AM Eastern Time
Conference Call: https://register-conf.media-server.com/register/BIa693ec3496b1413b8682b952b2ff9e10
Webcast: https://edge.media-server.com/mmc/p/rsj3o3mw

About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins. The Company develops long-acting, controlled-release drugs designed to deliver therapy precisely at the site of care, addressing critical unmet medical needs across a wide and diverse pipeline spanning surgical care, metabolic diseases, and beyond. PolyPid’s lead product, D-PLEX₁₀₀, successfully met its primary and all key secondary endpoints in the landmark Phase 3 SHIELD II trial for the prevention of surgical site infections. Guided by a commitment to precision and innovation, PolyPid is redefining how therapies perform and raise the standard of patient care. For additional Company information, please visit http://www.polypid.com and follow us on Twitter (X) and LinkedIn.

Company Contact:
PolyPid Ltd.
Ori Warshavsky
908-858-5995
IR@Polypid.com

Investor Relations Contact:
Arx Investor Relations
North American Equities Desk
polypid@arxhq.com

ROCKAWAY, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report its financial results for the third quarter ended September 30, 2026, after the market closes on Wednesday, November 4, 2026. Management will host a conference call and webcast at 4:30 PM EST that day to review the results and answer questions.

Participants may join by telephone or webcast using the details below.

Wednesday, November 4, 2026 at 4:30 pm EST
Participant Dial-In: 877-407-8835 / +1 201-689-8779
Conference ID #: 13763480
Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=af6qsd3k

A replay of the webcast will be available in the Investors section of the Company’s website at investor.electrocore.com.

About electroCore, Inc.
electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore® non-invasive vagus nerve stimulation (nVNS) and Quell® neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga™ and TAC-STIM™ nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.

For more information, visit www.electrocore.com.

Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com

NEW YORK, Oct. 29, 2026 (GLOBE NEWSWIRE) — The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading is halted in TJGC Group Limited (Nasdaq: TJGC) for additional information requested from the company. Previously, the Securities and Exchange Commission effected a trading suspension in TJGC from 04:00:00 on October 15, 2026 to 23:59:00 on October 28, 2026. The last sale price of the company’s shares was $31.89. 

More information about the SEC’s order can be found at
https://www.sec.gov/files/litigation/suspensions/2026/34-106668.pdf.

Trading will remain halted until TJGC Group Limited has fully satisfied Nasdaq’s request for additional information.

For news and additional information about the company, please contact the company directly or check under the company’s symbol using InfoQuotesSM on the Nasdaq® Web site.

For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com.

Nasdaq Contact:

Nasdaq MarketWatch
nasdaqmarketwatch@nasdaq.com

NDAQO

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report third quarter financial results on Thursday, November 5, 2026, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.

Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX’s website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call. An archived replay of the webcast will be available on the Company’s website.

About CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked PROBODY® therapeutics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), cytokines and T-cell engagers. CytomX’s clinical-stage pipeline includes varsetatug masetecan (Varseta-M; CX-2051) and CX-801. Varseta-M is a masked, conditionally activated ADC armed with a topoisomerase-1 inhibitor payload and directed toward epithelial cell adhesion molecule (EpCAM). EpCAM is a highly expressed tumor antigen that has previously been undruggable due to expression on normal tissues. Varseta-M is designed to open a therapeutic window for this high potential target and is initially being developed for the treatment of metastatic colorectal cancer. Varseta-M was discovered in collaboration with ImmunoGen, now part of AbbVie. CX-801 is a masked interferon alpha-2b PROBODY® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CX-801 is initially being developed for the treatment of metastatic melanoma. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).

Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com

Investor Contact:
Precision AQ
Stephanie Ascher
stephanie.ascher@precisionaq.com

Media Contact:
Precision AQ
Colleen Ketchum
colleen.ketchum@precisionaq.com

Dr. Bender brings a proven track record in therapeutic development, company evolution, and strategic execution to help guide Diagonal’s continued pipeline progress

Diagonal is advancing a portfolio of multispecific clustering antibodies that restore normal receptor signaling to enable development of disease-modifying therapies, including DIAG723, currently in a Phase 1/2 clinical trial for Hereditary Hemorrhagic Telangiectasia

WATERTOWN, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) — Diagonal Therapeutics, a clinical-stage biopharmaceutical company pioneering multispecific clustering antibodies to address the root causes of serious diseases, today announced the appointment of Jeremy Bender, Ph.D., M.B.A., as Chair of its Board of Directors, succeeding Michael Gladstone, who will continue to serve on the Board. Dr. Bender brings over 20 years of drug development experience and company leadership to Diagonal Therapeutics.

“Jeremy is an accomplished biotechnology leader, who most recently steered Day One Biopharmaceuticals from an early clinical-stage biotech through its first successful commercial launch. We are thrilled to welcome him as Board Chair of Diagonal,” said Alex Lugovskoy, Ph.D., Founder and Chief Executive Officer of Diagonal. “Jeremy’s drug development experience in rare disease, deep operational expertise, and track record across strategic business development will be invaluable as we continue to advance clinical development of our lead program, DIAG723, which represents a potentially transformative, disease-modifying therapeutic for people impacted by hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH). We’re extremely grateful to Michael Gladstone for his service as Diagonal’s founding Chair. Michael’s leadership has been fundamental in establishing Diagonal’s position as a leader in clustering antibody technology and driving the significant progress we have achieved across our pipeline. We look forward to his continued contributions as a Board member.”

Diagonal is currently enrolling patients in DIAMOND, a Phase 1/2 multicenter, randomized, double-blind, placebo-controlled trial evaluating DIAG723 in people living with HHT, a rare, serious genetic vascular disorder. The DIAMOND trial will include a multidose Phase 2 cohort (Part C) in people with HHT and concomitant PAH to assess safety and exploratory effects on HHT- and pulmonary-related measures.

“Diagonal’s approach is straightforward and powerful – identify diseases caused by loss-of-function alterations and design antibody therapeutics that seek to activate and restore function through direct binding to altered proteins. This differs from other approaches, which aim to compensate indirectly for loss of function by inhibiting downstream components,” said Dr. Bender. “I look forward to working with Alex, the Diagonal management team, and my fellow board members as we harness this novel science to address the root cause of disease for patients in need.”

Dr. Bender most recently served as Chief Executive Officer, President and a member of the board of directors of Day One Biopharmaceuticals from 2020 to 2026 where he led the company’s evolution into a commercial-stage oncology company, including the approval and launch of OJEMDA® for pediatric low-grade glioma and the company’s acquisition by Servier in 2026. Before Day One, he served as Vice President of Corporate Development at Gilead Sciences. Earlier in his career, Dr. Bender held executive leadership positions at Tizona Therapeutics (Chief Operating Officer), Sutro Biopharma (Chief Business Officer) and Allos Therapeutics (Vice President of Corporate Development), where he led corporate strategy, business development and operational execution. He began his career in the life sciences practice at Boston Consulting Group. Dr. Bender currently serves on the board of directors of Aura Biosciences, Bicara Therapeutics and Mereo BioPharma Group plc, and previously served on the board of Fusion Pharmaceuticals. He holds a B.S. in Biological Sciences from Stanford University, a Ph.D. in Microbiology and Immunology from the University of Colorado, and an M.B.A. from the MIT Sloan School of Management.

About Diagonal Therapeutics

Diagonal Therapeutics is a clinical-stage biopharmaceutical company pioneering multispecific clustering antibodies, a new class of biologics designed to address the root causes of serious diseases. Our clustering antibodies, derived from our proprietary DIAGONAL Product Engine, are designed to restore normal signaling by assembling receptors in the precise geometry required for activation in diseases that arise from deficient signaling pathways. Our lead product candidate, DIAG723, is a bispecific clustering antibody designed to restore normal activin receptor-like kinase 1 (ALK1) signaling, which is deficient in both hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH). For more information, please visit www.diagonaltx.com.

Media Contact:
media@diagonaltx.com

PLANO, Texas, Oct. 29, 2026 (GLOBE NEWSWIRE) — Deep Isolation Nuclear, Inc. (“Deep Isolation” or the “Company”), a leading innovator in nuclear waste disposal technology, today announced it will report its third quarter 2026 earnings before the market opens on Thursday, November 12th, 2026.

An updated presentation will be posted to the investor relations website concurrent with the earnings release.

About Deep Isolation

Deep Isolation (OTCQB: DBHL) is the first company to undertake development of technologies for nuclear waste disposal in deep boreholes. Deep Isolation’s solution will offer a unique approach to help countries identify, plan for and complete the necessary steps to dispose of their nuclear waste inventories. With over 100 patents issued to date, Deep Isolation’s technology is designed to leverage proven drilling practices to allow safe isolation of waste deep underground in horizontal, vertical, or slanted borehole repositories. Deep Isolation’s Universal Canister System is engineered to support integrated management of spent fuel and high-level radioactive waste from legacy and advanced reactors across storage, transportation, and eventual disposal. In January 2026, Deep Isolation launched a full-scale, at-depth deep borehole Commercialization Pilot for its solution at Cameron, Texas, in collaboration with the Deep Borehole Demonstration Center, Halliburton (NYSE: HAL), Amentum (NYSE: AMTM), NAC International (TYO: 7004), and Occlusion Nuclear Solutions.

For more information, visit: deepisolation.com

Media Contact:
Sophie McCallum
media@deepisolation.com

Investor Contact:
Caldwell Bailey
InvestorRelations@deepisolation.com

Forward-Looking Statements

Statements contained in this news release that are not historical facts are “forward-looking information” or “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements regarding our plans, objectives and expectations for our business, the future growth of our business and the nuclear energy and nuclear waste disposal industries as a whole, and future benefits expected to arise from our strategic partnerships. In certain cases, forward-looking statements can be identified by the use of words and phrases or variations of words and phrases or statements such as “may,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “will,” “could,” “project,” “target,” “potential,” “continue” and similar expressions. Forward-looking statements are based on management’s belief and assumptions, including current expectations and projections about future events and trends, and on information currently available to management.

Forward-looking statements in this or any other news release are subject to a number of risks, uncertainties, and assumptions that could cause actual results to be materially different from those expressed or implied by such forward-looking statements. Such risks, uncertainties, and assumptions are subject to a number of factors, including, among others: the failure of a market to develop for our deep borehole disposal solutions as quickly as we expect or at all; a failure of demand for our solution to develop sufficiently; regulatory and legal developments, including issues relating to obtaining regulatory approvals or permissions on the timelines we expect or at all; our lack of profitability; delays or failure in our initiative to complete a full-scale, at-depth demonstration of our Universal Canister System and our deep borehole solution; our failure to enter into contracts with customers or, once we do enter into contracts, to continue such contractual relationships or to receive new contract awards; our dependency on governmental contracts and awards; our failure to manage our growth effectively or to execute our business plan; a failure to sustain and expand relationships with governmental entities and strategic partners; failure in the assumptions or analyses we have used in supporting forecasts or plans; our inability to commercialize our products at scale; the development or deployment of other technologies or solutions supplanting or competing with our technologies; challenges to our intellectual property; failures to protect, maintain, enforce, and enhance our intellectual property, and claims by others of intellectual property infringement; political and public perceptions of nuclear energy, including perceptions as to accidents or other high-profile events involving nuclear power facilities or radioactive materials; our liquidity and ability to raise capital; any inability to control operating and project costs and project delays or other project-related problems; security (including cybersecurity) breaches or disruptions; geopolitical, macroeconomic, domestic events or crises, including supply chain disruptions and other risks and uncertainties outside of our control; weather and effects of climate change; and litigation or legal proceedings that may be brought against us.

The foregoing is not an exhaustive list of all the factors that may cause any forward-looking statements to prove inaccurate or our actual results to differ materially from our expectations and forecasts. Moreover, we operate in a highly regulated environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the future events and trends discussed in this release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements, and we cannot guarantee future results, performance, or achievements. Accordingly, readers should not place undue reliance on forward-looking statements. We undertake no obligation to update any forward-looking statements for any reason after the date of this release or to conform these statements to actual results or revised expectations, except as required by law. ”

Additional information concerning the factors above and other factors will be found in the Company’s public filings with the Securities and Exchange Commission (the “SEC”), including the sections titled “Forward-Looking Statements” and “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 filed with the SEC on November 14, 2025, our Form S-1, originally filed August 18, 2025 and subsequently amended, our Proxy Statement for our 2026 Annual Meeting as filed on April 29, 2026, and in filings with the SEC that will be made in the future. The Company’s SEC filings are available free of charge at www.sec.gov or upon written request to Deep Isolation Nuclear at InvestorRelations@deepisolation.com.

IRVINE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) — Shimmick Corporation (“Shimmick”) (Nasdaq: SHIM), a national leader in complex infrastructure solutions, today announced that the company will release its third quarter 2026 financial results after market close on Thursday, November 12, 2026.

Shimmick will also host a video webcast conference call to discuss those results at 4:30 p.m. Eastern Time on the same day. The conference call will be live-streamed via the Company’s Investor Relations website (https://investors.shimmick.com/). A copy of the earnings call presentation will also be posted to our website.

A replay of the video webcast will be available through the same link following the conference call for a limited time beginning immediately following the call.

About Shimmick Corporation
Shimmick Corporation (NASDAQ: SHIM) is an industry leader in delivering turnkey infrastructure solutions that strengthen critical markets across water, energy, climate resiliency, and sustainable transportation. The Company integrates technical excellence with collaborative project delivery methods to provide innovative, technology-driven infrastructure solutions that accelerate economic growth and empower communities nationwide. With a track record spanning more than a century, Shimmick combines deep engineering heritage with an entrepreneurial spirit to solve today’s most complex infrastructure challenges. For more information, visit www.shimmick.com.

Contact:         

Investor Relations
+1-949-704-2350
IR@shimmick.com

Media
Lee Ann Ballew
LeeAnn.Ballew@shimmick.com 

MIAMI, Oct. 29, 2026 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its third quarter financial results on Thursday, November 12, 2026. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights.

Parties interested in participating by phone should register using this online form. After registering for the webcast, dial-in details will be provided in an auto-generated e-mail containing a link to the conference phone number along with a personal pin. A live audio webcast and an archive of the recording will be available here and through the Investors page of InspireMD’s corporate website at https://investors.inspiremd.com. Interested participants are encouraged to register more than 15 minutes before the start of the call.

About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com.

Investor Contact:
Jeff Warren
LifeSci Advisors
jwarren@lifesciadvisors.com
investor-relations@inspiremd.com

NASHVILLE, Tenn., Oct. 29, 2026 (GLOBE NEWSWIRE) — Truxton Corporation (OTCID: TRUX), a financial holding company and the parent of Truxton Trust Company, announced that its Board of Directors has approved a quarterly cash dividend of $0.22 per common share payable December 24, 2026, to shareholders of record as of December 10, 2026.

About Truxton
Truxton is a premier provider of wealth, banking, and family office services for wealthy individuals, their families, and their business interests. Serving clients across the world, Truxton’s vastly experienced team of professionals provides customized solutions to its clients’ complex financial needs. Founded in 2004 in Nashville, Tennessee, Truxton upholds its original guiding principle: do the right thing. Truxton Trust Company is a subsidiary of financial holding company, Truxton Corporation (OTCID: TRUX). For more information, visit truxtontrust.com.

Investor Relations 
Austin Branstetter
615-250-0783
austin.branstetter@truxtontrust.com
Media Relations
Swan Burrus
615-250-0773
swan.burrus@truxtontrust.com

NEW YORK, Oct. 29, 2026 (GLOBE NEWSWIRE) — Nexxen International Ltd. (NASDAQ: NEXN) (“Nexxen” or the “Company”), the advertising technology platform powered by unique data and media, will release its financial results for the three and nine months ended September 30, 2026, before the U.S. market opens on Thursday, November 12, 2026.

The Company will host a webcast and conference call at 9:00 AM ET on the same date to discuss its financial results and outlook.

Webcast and Conference Call Details

  • When: November 12, 2026, at 9:00 AM ET
  • Webcast: A live and archived webcast can be accessed from the Events and Presentations section of Nexxen’s Investor Relations website at https://investors.nexxen.com/
  • Participant Dial-In Numbers:
    • U.S. / Canada Toll-Free Dial-In Number: (888) 596-4144
    • U.K. Toll-Free Dial-In Number: +44 800 260 6470
    • International Dial-In Number: +1 (646) 968-2525
    • Conference ID: 4150652

About Nexxen

Nexxen is the advertising technology platform that delivers full-funnel performance powered by unique data and media. Comprised of a demand-side platform (“DSP”) and supply-side platform (“SSP”), with the Nexxen Data Platform at its core, we meet the demands of today’s converging media landscape with exclusive audience intelligence, automation and expertise.

Headquartered in Israel, Nexxen maintains offices throughout North America, Europe and Asia-Pacific and is traded on Nasdaq (NEXN). For more information, please visit nexxen.com.

For further information please contact:

Nexxen International Ltd.
Billy Eckert, Vice President of Investor Relations
ir@nexxen.com

Genevieve Wheeler, Senior Director of Communications
gwheeler@nexxen.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.